Trown P W, Wills R J, Kamm J J
Cancer. 1986 Apr 15;57(8 Suppl):1648-56. doi: 10.1002/1097-0142(19860415)57:8+<1648::aid-cncr2820571303>3.0.co;2-o.
Interferon alfa-2a (Roferon-A, Hoffmann-La Roche Inc., Nutley, NJ) is identical to one of approximately 15 subtypes of interferon alpha made by human leukocytes and is produced in bacteria using recombinant DNA techniques. In its antiviral, antiproliferative, and immunomodulatory activities it is similar to leukocyte interferon alpha. These activities are species-restricted and have been demonstrable, thus far, only in humans, certain other primates, bovines, and guinea pigs or cells derived therefrom. The possibility that the toxicity of interferon alfa-2a would also be species-restricted appears to have been confirmed by results obtained thus far. Toxicological studies in rats, mice and several species of monkeys have failed to indicate the side effects that have been observed in humans. However, studies in species in which interferon alfa-2a is active and in others in which it is not, have revealed similar pharmacokinetics and elimination mechanisms.
干扰素α-2a（罗扰素，霍夫曼-罗氏公司，新泽西州纳特利）与人类白细胞产生的约15种α干扰素亚型之一相同，它是利用重组DNA技术在细菌中生产的。在抗病毒、抗增殖和免疫调节活性方面，它与白细胞α干扰素相似。这些活性具有种属限制性，迄今为止仅在人类、某些其他灵长类动物、牛、豚鼠或源自它们的细胞中得到证实。干扰素α-2a的毒性也具有种属限制性这一可能性似乎已被迄今为止获得的结果所证实。对大鼠、小鼠和几种猴子进行的毒理学研究未能表明在人类中观察到的副作用。然而，对干扰素α-2a有活性的物种和无活性的其他物种进行的研究显示了相似的药代动力学和消除机制。
